Results for this period
Interim period (second quarter)1 January 2026–30 June 2026Non-consolidated (standalone)Japanese GAAPThe width of the band at each stage is based on revenue. The narrower it becomes toward the bottom, the smaller the proportion of revenue that remains as profit. The dotted outline is the full-year forecast and the band inside it is the result for this period. The progress rate is the result divided by the forecast.
塗りつぶした部分が自己資本比率です。総資産のうち、返済のいらない自前の資金がどれだけかを表します。The thin vertical line indicates the level at the end of the previous fiscal year.
Stacked from zero: upward is an increase in cash, downward a decrease (in ¥ thousand).The net change represented by the dotted line is the total of three items, calculated from figures provided by the company.
Revenue from research support services for pharmaceutical companies declined, while revenue related to biosimilars expanded. Research and development expenses declined year on year, mainly because clinical development-related expenses decreased, narrowing losses at each stage.
None ("There are no applicable matters.")
| Item | Details |
|---|---|
| Fiscal Period Classification | Interim period (second quarter) |
| Accounting standards | Japanese GAAP |
| Consolidated / non-consolidated | Non-consolidated (standalone) |
| Period Covered | 1 January 2026–30 June 2026 |
| Net Sales | ¥273 million (YoY +8.7%) |
| Operating profit | ¥-479 million |
| Ordinary income | ¥-481 million |
| Profit attributable to owners of the parent | ¥-483 million |
| Net income per share | -¥6.62 |
| Equity ratio | End of the current fiscal period 81.9 / End of previous period 64.1 |
| Total assets | ¥1,907 million |
| Net assets | ¥1,565 million |
| Cash flows from operating activities | ¥-538,823 thousand |
| Cash flows from investing activities | ¥-3,733 thousand |
| Cash flows from financing activities | ¥709,553 thousand |
| Cash and cash equivalents at end of period | ¥1,372,022 thousand |
| Full-year earnings forecast | Net Sales ¥600 million / Operating profit Not disclosed / Ordinary income Not disclosed / Net income Not disclosed / Company-wide earnings forecast Not disclosed |
| Revision to Earnings Forecast | Net Sales No / Operating profit No / Ordinary income No / Net income No / Remarks No changes to the most recently published earnings forecasts |
| Annual Dividend Forecast | ¥0 → ¥0（0.0%） |
| Segment revenue | Drug Discovery Business Not disclosed / Drug Discovery Support Business ¥273,659 thousand |
| Segment profit | Drug Discovery Business ¥-368,984 thousand / Drug Discovery Support Business ¥158,522 thousand |
| Depreciation and amortization | ¥4,831 thousand |
| Breakdown of extraordinary income (loss) | Current interim period Extraordinary income None (total: -) / Extraordinary loss No |
| Disclosure regarding the going concern assumption | None ("There are no applicable matters.") |
| Change in accounting policy | Changes due to revisions to standards No / Other changes No / Change in accounting estimate No / Restatement No |
| Material subsequent events | Between the end of the interim accounting period and 31 July 2026, part of the 23rd Series Stock Acquisition Rights was exercised, and 2,209,800 common shares were issued. Capital stock and the capital reserve each increased by ¥75.375 million, and the total number of issued shares as of 31 July 2026 was 81,150,000. |
| Availability of Supplementary Financial Results Materials | Yes |
| Availability of Financial Results Briefing | Yes (for institutional investors and securities analysts) |
| Issued Shares at Period-End | 78,940,200 |
| Treasury Shares at Period-End | 22,819 |
| Factors Behind Changes in Business Performance | Revenue from research support services for pharmaceutical companies declined, while revenue related to biosimilars expanded. Research and development expenses declined year on year, mainly because clinical development-related expenses decreased, narrowing losses at each stage. |
Items this document does not state (7)
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.Revenue increased as sales related to biosimilars expanded, despite a decline in revenue from research support services for pharmaceutical companies. The deficit at the operating and other levels narrowed mainly because clinical development-related expenses recognized during the period decreased from the same period of the previous year, reducing research and development expenses by ¥26.884 million.